脂肪酸合成酶抑制因子筛选鉴定分选连接蛋白8为NAFLD治疗靶点
该研究通过FASN复合蛋白 interactomics 分析筛选出SNX8为FASN结合伙伴,SNX8招募E3连接酶TRIM28促进FASN泛素化降解,从而抑制肝细胞脂质沉积。Snx8敲除小鼠NAFLD加重,而肝细胞特异性过表达Snx8可抑制HFHC饮食诱导的肝脂肪变性,且保护作用依赖于FASN抑制。
要点
- SNX8直接结合FASN并招募TRIM28促进其泛素化降解。
- 肝细胞Snx8缺失加重小鼠NAFLD,过表达则抑制HFHC饮食诱导的脂肪变性。
- 靶向SNX8-FASN轴是NAFLD防治的潜在策略。
核心结论
- SNX8是NAFLD的关键抑制因子,通过促进FASN蛋白酶体降解发挥作用。
- 靶向SNX8-FASN轴是NAFLD预防和治疗的有前景策略。
研究设计与样本
- 通过FASN复合蛋白的系统性interactomics分析筛选FASN结合蛋白。
- 在体外肝细胞中干扰或过表达Snx8,并在Snx8敲除小鼠及肝细胞特异性过表达Snx8小鼠中验证。
主要发现
- SNX8直接结合FASN,促进FASN泛素化及蛋白酶体降解。
- SNX8通过招募E3连接酶TRIM28并增强TRIM28-FASN相互作用介导FASN降解。
- 肝细胞干扰Snx8加重体外脂质积累,SNX8过表达阻断肝细胞脂质沉积。
- Snx8敲除小鼠较野生型对照肝脏脂肪变性和脂质合成通路显著加重。
- 肝细胞特异性过表达Snx8显著抑制HFHC饮食诱导的肝脂肪变性,保护作用 largely 依赖FASN抑制。
临床怎么用
- SNX8-FASN轴可作为NAFLD治疗靶点进行进一步药物开发。
- SNX8表达或活性可能作为NAFLD干预的潜在方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: NAFLD is the most prevalent chronic liver disease without any Food and Drug Administration-approved pharmacological intervention in clinic. Fatty acid synthase (FASN) is one of the most attractive targets for NAFLD treatment because of its robust rate-limiting capacity to control hepatic de novo lipogenesis. However, the regulatory mechanisms of FASN in NAFLD and potential therapeutic strategies targeting FASN remain largely unknown. METHODS AND RESULTS: Through a systematic interactomics analysis of FASN-complex proteins, we screened and identified sorting nexin 8 (SNX8) as a binding partner of FASN. SNX8 directly bound to FASN and promoted FASN ubiquitination and subsequent proteasomal degradation. We further demonstrated that SNX8 mediated FASN protein degradation by recruiting the E3 ligase tripartite motif containing 28 (TRIM28) and enhancing the TRIM28-FASN interaction. Notably, Snx8 interference in hepatocytes significantly deteriorated lipid accumulation in vitro, whereas SNX8 overexpression markedly blocked hepatocyte lipid deposition. Furthermore, the aggravating effect of Snx8 deletion on NAFLD was validated in vivo as hepatic steatosis and lipogenic pathways in the liver were significantly exacerbated in Snx8-knockout mice compared to wild-type controls. Consistently, hepatocyte-specific overexpression of Snx8 in vivo markedly suppressed high-fat, high-cholesterol diet (HFHC)-induced hepatic steatosis. Notably, the protective effect of SNX8 against NAFLD was largely dependent on FASN suppression. CONCLUSIONS: These data indicate that SNX8 is a key suppressor of NAFLD that promotes FASN proteasomal degradation. Targeting the SNX8-FASN axis is a promising strategy for NAFLD prevention and treatment.
引用
- Hu Y, He W, Huang Y, et al. Fatty Acid Synthase-Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLD. Hepatology. 2021. PMID: 34231239. doi:10.1002/hep.32045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。